Effect of bright light on mood and sleep in Parkinson's disease

Completed

• Conditions: Slaapstoornissen en -afwijkingen; Parkinson's disease; shaking palsy; 10028037; 10027946

• Registration Number: NL-OMON41275
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Diagnosis of Parkinson's Disease
Stably established on psychotropic medication (>4wk) or off medication for >4wk

Exclusion Criteria

psychosis
mania
suicidality
medication inducing retinal photosensitivity
retinopathy
having had BLT before

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measure is the percent change in score on the Hamilton<br /><br>Depression Rating Scale (HDRS) and Geriatric Depression Scale (GDS-30) between<br /><br>baseline and end of treatment (immediate effect) and between baseline and six<br /><br>months of follow-up (enduring effect). In addition, the Numbers Needed to Treat<br /><br>(NNT) on the basis of dichotomous treatment response (>50% reduction in<br /><br>HDRS-score immediately after treatment).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome measures are the change in score for measures of sleep<br /><br>(SCOPA-sleep), motor function (UPDRS-III), Quality of Life (WHOQOL-bref, ZBI)<br /><br>and circadian rhythms (actigraphy, cortisol morning curve and melatonin evening<br /><br>curve).</p><br>